EMA Authorised: Descovy (emtricitabine;tenofovir alafenamide) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA authorised Descovy (emtricitabine and tenofovir alafenamide) for HIV infections; MAH: Gilead Sciences Ireland UC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Descovy (emtricitabine/tenofovir alafenamide)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Gilead Sciences Ireland UC. Decision date: 16/02/2023